AstraZeneca PLC · LSE:AZN
AstraZeneca — Goldman Sachs Healthcare Conference 2004
26 slides from AstraZeneca's conference presentation, June 2004
Slide 1: Goldman Sachs Conference
Goldman Sachs Conference June 2004
Slide 2: AstraZeneca strategy
AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potential of growth portfolio Drive Productivity for competitive Sustainable Platform for advantage growth for growth Expand long term Next wave of development projects In-house discovery External collaboration Broaden
Slide 3: 2004 priorities
2004 priorities Continue to build Crestor® into megabrand Drive Oncology portfolio Progress to US market leadership for Nexium® and Seroquel® First launches for Exanta® and register chronic claims Advance development projects Continuous improvement in productivity 2004 EPS range in range of $2. 00 t
Slide 4: Crestor
Crestor® First launch Feb 03 (Netherlands) US launch Sept 03 Crestor® profile • Lowers LDL-C by up to 63% across the dose range • Gets more patients to goal • HDL-C raising is maintained across dose range • Well tolerated, safety profile comparable to other marketed statins Approved in over 60 marke
Slide 5: Crestor: STELLAR study
Crestor®: STELLAR study LDL-C lowering across the dose range LDL-C: LS mean change from baseline at week 6 ! ! #$ % $ $ """ % $$ """ """ """ & % $$ """ """ """ ! "!# $ " %&" ' () *+ , - 5
Slide 6: Crestor – Change to EU label
Crestor – Change to EU label Patient safety through optimal use of our products is our highest priority CRESTOR delivers the greatest reduction of LDL-C EU prescribing information changes address the small percentage of patients at high risk of myopathy who required the 40mg dose Reported cases were
Slide 7: Reporting rates of rhabdomyolysis with statin therapy
Reporting rates of rhabdomyolysis with statin therapy 0" 7 '." . " # ' '." #.8 9! :' : /0 4 " 2 5 ' !6!"1 " 3 % $$ 22 !6!" )*% $ $ *% $$ 3 #$ % $ $ ' . "%" + % $$ 3 5 /0%" 1 & % $$ . "%" 3- % $$ $ $$ . %" 1 3 $ $$ ,- % $$ ." *% $ $ 3 ." 4. 0 3 !'(( ('(( !' (' !' (' !' (' '! ' ! '(( ' ' ' ' ' ' ' ! '
Slide 8: Reporting rates of fatal rhabdomyolysis with statin therapy
Reporting rates of fatal rhabdomyolysis with statin therapy 0" 7 '." . " # ' '." # '.8 9! :' : /0 4 " 2 5 ' !6!"4 " 3 + % $$ !6!" 22 )*% $ $ *% $$ 3 ' #$ % $ $ . "%" + % $$ 3 + 5 /0 %" 1 & % $$ . "%" % $$ 3 $ $$ . %" 1 $ $$ ,- % $$ 3+ ." *% $ $ 3 ." 4. 0 !'(( ('(( !' (' !' (' !' (' ' ! '! '(( ' ' '
Slide 9: Crestor Benefit:Risk Muscle Effects
Crestor® Benefit:Risk Muscle Effects CK >10 x ULN: Frequency by LDL-C Reduction . 7 ; < ; < 23+4 ( 0 ; < % ; < + 4" ; ( < 01 + - --* + ( + - = +.+ /*-$ Brewer HB. Am J Cardiol 2003;92(Suppl):23K–29K 9
Slide 10: Crestor: early launch markets
Crestor®: early launch markets > 5 > (5 .AB ?" 08 "2 > -> 5 > !5 5 > > > 6? 6? 6? 6?( 6? 6?+ 6?- 4 ! " 8" ' ! /@ /0 1" Source: AZ CRESTOR Launchtrak System (Data source: please see country reports) Data displayed in share of total prescriptions & tablets dispensed 10 Market = Selected C10A1/USC 3211
Slide 11: Crestor: US launch dynamic share
W k1 (W W E 0% 10% 20% 30% 40% 50% k3 19 (W /0 Market = USC 32110 9/ W E 03 k5 03 ) (W /1 0/ W E 03 k7 17 ) (W /1 0/ W E 03 k9 31 ) (W /1 0/ W CRESTOR E 03 k1 14 ) 1 /1 (W 1/ W E 03 k1 28 ) 3 /1 (W 1/ W E 03 k1 ) Lipitor 12 5 /1 (W 2/ W E 03 k1 26 ) 7 /1 (W 2/ W E 03 k1 09 ) Zocor 9 /0 (W 1/ W E Sou
Slide 12: Oncology - A Global leader
Oncology - A Global leader Casodex® - class leader (+22% $854 million) • Early prostate cancer Faslodex® - first in class ($77 million) • EU launches from 2Q 2004 Iressa® - first in class ($228 million) • Japan $101 million • US $102 million - >42,000 retail Rx’s dispensed* Arimidex® - class leader
Slide 13: Iressa
Iressa Tarceva (BR-21) – ASCO 2004 • Validates the EGFR-TKi hypothesis and targeted therapy approaches to cancer • Iressa EAP 12 month survival data comparable with outcomes on BR-21; response rates comparable with IDEAL • AstraZeneca study (ISEL) progressing well Science and NEJM data - significant
Slide 14: Iressa survival: Promising a better future for patients
Iressa® survival: Promising a better future for patients 1.0 0.8 ~ 30% survival at 1 year Massarelli et al 3rd & 4th line Reference data 0.6 Iressa® IDEAL 1 Iressa® IDEAL 2 Iressa® EAP survival USA 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Months from randomization 14
Slide 15: Seroquel
Seroquel® Full year sales $1,487 million; up 27% CER Q1 04 sales $448 million; down 2% CER Atypical market growth continues Seroquel gaining market share Mix improvement New indication • Bipolar mania approved in US and EU New data • Bipolar depression data (BOLDER Study) – APA ‘04 *Source: IMS Heal
Slide 16: US: Trends in Antipsychotics
US: Trends in Antipsychotics 1998 - 2003 50 $10,000 TYPICAL RXs 45 $9,000 ATYPICAL RXs 40 TYPICAL SALES 13% $8,000 ATYPICAL SALES 35 87% $7,000 RXs (Millions) Sales (Millions) 30 $6,000 25 30% $5,000 % 20 $4,000 15 55% $3,000 70% 10 $2,000 5 $1,000 45% 0 $0 9 99 9 0 00 0 01 01 1 2 02 2 3 03 3 r-9 -9
Slide 17: Europe: Trends in Antipsychotics
Europe: Trends in Antipsychotics 1998 - 2003 45 TYPICAL RXs $2,500 ATYPICAL RXs 40 TYPICAL SALES ATYPICAL SALES $2,000 35 Sales (Millions USD) 30 $1,500 Rxs (Millions) 25 20 62% $1,000 15 85% 80% 10 38% $500 5 20% 15% 0 $0 MAT MAT MAT MAT MAT MAT MAT MAT MAT MAT MAT Q4/98 Q2/99 Q4/99 Q2/00 Q4/00 Q2/
Slide 18: Seroquel: US NRx in anti-psychotic market
0% 5% 10% 15% 20% 25% 30% 35% Jan-00 Feb-00 Mar-00 Apr-00 Market share May-00 Jun-00 Jul-00 Aug-00 market Sep-00 Oct-00 Nov-00 Dec-00 Jan-01 Feb-01 Mar-01 Apr-01 May-01 Jun-01 Jul-01 Aug-01 Sep-01 Oct-01 Nov-01 Dec-01 Jan-02 Feb-02 Mar-02 Apr-02 May-02 Jun-02 Jul-02 Aug-02 Sep-02 Oct-02 Nov-02 Sourc
Slide 19: Meeting More Patient Needs With Seroquel
Meeting More Patient Needs With Seroquel Mania Schizophrenia Bipolar Maintenance Depression 19
Slide 20: Seroquel Bipolar Mania
Seroquel® Bipolar Mania Change from baseline (YMRS) 0 * p<0.05 ** p<0.01 *** p<0.001 -5 * ** Placebo -10 *** -15 *** *** *** Seroquel® -20 *** *** *** -25 47 14 21 28 42 56 70 84 Day YMRS – Young mania rating scale Sachs et al Bipolar Disorders 2004: 6: 213 20
Slide 21: Seroquel Bipolar Depression
Seroquel® Bipolar Depression Study Week 0 1 2 3 4 5 6 7 8 0 Mean Change From Baseline (MADRS) Quetiapine 600 mg (n=170) Quetiapine 300 mg (n=172) -5 Placebo (n=169) * -10 * * * * * -15 * * * * * * * * * * -20 MADRS, Montgomer y-As berg Depressi on R ating Sc ale *P<0.001 (vs placebo) ITT, LOCF 21 Ca
Slide 22: Nexium US TRx PPI market share
Nexium® US TRx PPI market share 60% Total Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% 00 0 0 01 1 1 02 2 2 03 3 3 04 4 0 1 2 3 -0 l-0 r- 0 l-0 -0 l-0 -0 l-0 0 -0 -0 -0 -0 n- n- n- n- n- r- pr pr pr Ju Ju Ju Ju ct ct ct ct Ap Ap Ja Ja Ja Ja Ja A A A O O O O Prilosec® Nexium® Prevacid® Omep
Slide 23: US PPI market - TRx growth trends
US PPI market - TRx growth trends* Q103 Q203 Q303 Q403 Q104 30% 26% 19% 20% 14% 14% 13% 12% 10% 10% 1% 0% -2% -10% -20% -30% -40% -35% -50% -44% PPI Omeprazole PPI ex-omep Nexium® *TRx growth rates versus same period in the prior year 23
Slide 24: Exanta - Oral Direct Thrombin Inhibitor
Exanta® - Oral Direct Thrombin Inhibitor Prompt onset and offset of anticoagulation Wider therapeutic margin than warfarin Predictable pharmacokinetics Low potential for food and drug interactions No dose adjustment No coagulation monitoring Elevation of ALAT in some patients OS indication (EU) • Fi
Slide 25: 2004 Outlook
2004 Outlook Top-tier financial performance overriding objective • 2004 target EPS $2.00 - $2.15 Sales • Mid-teen growth (including currency) Costs and margins • Further gross margin improvement • SG&A / R&D high teens (including currency) • Currency offset on operating margin Key sensitivities • Cr
Slide 26: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with
AstraZeneca — Goldman Sachs Healthcare Conference 2004 on 6ix